Placebo + Cariprazine
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Sep 27, 2011 → Sep 3, 2014
NCT ID
NCT01412060About Placebo + Cariprazine
Placebo + Cariprazine is a phase 3 stage product being developed by Richter Gedeon for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01412060. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01469377 | Phase 2 | Completed |
| NCT01412060 | Phase 3 | Completed |
| NCT01396447 | Phase 2 | Completed |
Competing Products
20 competing products in Schizophrenia